New hope for AL amyloidosis patients who failed first-line therapy
NCT ID NCT04270175
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding daratumumab back to pomalidomide and dexamethasone can improve complete remission rates in 15 adults with relapsed or refractory AL amyloidosis who have already received daratumumab. Participants receive the three-drug combination to control the disease. The goal is to see if this approach works better than pomalidomide and dexamethasone alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston University Medical Center
Boston, Massachusetts, 02118, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Weill Cornell Medicine - Multiple Myeloma Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- New scan spots hidden organ damage before symptoms start
- Could a simple scan unlock better heart treatment?